title: Influence of cardiac output on peak t-PA plasma levels in patients receiving thrombolytic therapy with recombinant tissue-type plasminogen activator--correlation with patency rate.
abstract: We studied 35 consecutive patients with short onset of myocardial infarction who underwent thrombolytic therapy with rt-PA at a standard dosage regimen of 100 mg rt-PA total (10 mg given as a bolus followed by 50 mg, 20 mg and 20 mg per hour for 3 hours). These patients were monitored for t-PA antigen and t-PA activity and PAI-1 activity plasma levels during rt-PA infusion. Success or failure of thrombolytic therapy was evaluated by non-invasive criteria (early plasma creatine kinase peaks, early peak plasma myoglobin values, and electrocardiographic criteria) as well as by means of coronary angiography at the fourth day after thrombolytic treatment. In 24 (68.6%) of these patients a success of thrombolytic therapy could be established by these criteria, while 11 patients did not respond to thrombolytic therapy. Fifteen patients (14 responders and one non-responder) had to be excluded from the further evaluation because in these patients clinical laboratory data obtained upon admission before initiation of thrombolytic therapy were not complete. Therefore, 20 patients (10 responders and 10 non-responders) could further be analysed. The two groups of patients were not significantly different in body weight, body weight index, age, gender, liver or kidney functional parameters as determined before initiation of the thrombolytic therapy. Furthermore, PAI-1 plasma levels before initiation of thrombolytic therapy were not significantly different in the two groups, as were rt-PA dosage per body weight or body weight index.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Cardiology, University of Vienna, Austria.
authors.forename: K
authors.initials: K
authors.lastname: Huber
authors.forename: R
authors.initials: R
authors.lastname: Beckmann
authors.forename: P
authors.initials: P
authors.lastname: Probst
authors.forename: F
authors.initials: F
authors.lastname: Rauscha
authors.forename: F
authors.initials: F
authors.lastname: Kaindl
authors.forename: B R
authors.initials: BR
authors.lastname: Binder
mesh_terms: D000328:Adult; D000368:Aged; D002302:Cardiac Output; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood / Q000503:physiopathology; D011994:Recombinant Proteins / Q000097:blood / Q000627:therapeutic use; D015912:Thrombolytic Therapy / Q000379:methods*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000097:blood / Q000627:therapeutic use*; D014654:Vascular Patency / Q000502:physiology*
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator